Showing results (181-190 of 216) with videos related to

Sort By:
Pageof 22
ESMO Open|December 22, 2024
HER2DX genomic test in early-stage HER2-positive breast cancerS M Tolaney, N Tung, A C Wolff, et al.
ESMO Open|July 7, 2026
Molecular effects of ovarian stimulation for fertility preservation in breast cancer: a paired-biopsy analysisY Barral El Gaoui, F Brasó-Maristany, A Borrás Capó, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 12, 2015
Home management of acute medical complications in cancer patients: a prospective pilot studyC Font, F Fernández-Avilés, C Calderon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2019
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant studyV Guarneri, M V Dieci, G Bisagni, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|September 8, 1999
Echocardiographic parameters of the freestyle stentless bioprosthesis in aortic position: the European experienceL H Baur, X Y Jin, Y Houdas, et al.
ESMO Open|April 19, 2023
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysisF Schettini, O Martínez-Sáez, C Falato, et al.
Oncogene|February 18, 2014
SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer modelG Kim, M Ouzounova, A A Quraishi, et al.
ESMO Open|March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)G Villacampa, T Pascual, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockadeP Nuciforo, T Pascual, J Cortés, et al.
ESMO Open|October 1, 2025
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancerS Morganti, R J Kusmick, M E Hughes, et al.
Pageof 22